About the Ocular Genetics and Gene Therapy Session
Ocular Genetics and Gene Therapy explores the genetic and molecular basis of inherited eye diseases and the development of targeted genomic treatments. The session covers genomic diagnosis, inherited retinal and optic nerve disorders, genetic counseling, gene replacement, gene editing, molecular technologies, and advances toward personalized genetic therapies.
Abstract Scope and Participation
Submissions may address inherited eye disorders, genomics, molecular diagnostics, genetic variants, counseling, gene therapy, gene editing, vectors, and therapeutic outcomes. Ophthalmologists, geneticists, molecular scientists, researchers, counselors, and professionals involved in genomic medicine and therapeutic development are encouraged to participate.
Topics Covered in Ocular Genetics and Gene Therapy
Topic 01
Ocular Genetics
Topic 02
Genomic Diagnostics
Topic 03
Inherited Eye Diseases
Topic 04
Gene Therapy
Topic 05
Genetic Counseling
Topic 06
Gene Editing
Featured Speakers — Ocular Genetics and Gene Therapy 2027
Recent Research Presented at Ocular Genetics and Gene Therapy Sessions
Lenadogene nolparvovec gene therapy in Leber hereditary optic neuropathy
Leber Hereditary Optic Neuropathy (LHON) is a rare, maternally inherited mitochondrial genetic disorder characterized by sudden, painless vision loss, and represents a significant unmet medical need.…
From bench to bedside: Gene therapy for inherited retinal diseases — current evidence, emerging therapies and the global challenge of equitable access
Background: Inherited Retinal Diseases (IRDs) are a clinically and genetically heterogeneous group of conditions causing progressive visual impairment, affecting approximately 5.5 million people…
Quality of life in inherited retinal dystrophies: A systematic review
Inherited retinal dystrophies (IRDs) are a leading cause of visual impairment in people aged 15–45 years, affecting an estimated 5.5 million people worldwide, predominantly through retinitis…
Lumevoq gene therapy in leber hereditary optic neuropathy
Leber Hereditary Optic Neuropathy (LHON) is a rare, maternally inherited mitochondrial genetic disorder characterized by sudden, painless vision loss. The disease has a significant unmet medical need…
Lumevoq gene therapy in leber hereditary optic neuropathy
Leber hereditary optic neuropathy (LHON) is a rare, maternally inherited mitochondrial genetic disease with a high unmet medical need. Three primary point mutations in the mtDNA are responsible for…
Stickler syndrome. Clinical presentation and outlook
Stickler Syndrome is an uncommon frequently undiagnosed multisystem collagenopathy with significant genetic and phenotypic heterogeneity, a condition that carries a risk for significant ocular…
Related Scientific Sessions at IOC 2027
Why Attend the Ocular Genetics and Gene Therapy Conference 2027
Present Your Research
Oral and poster slots for original Ocular Genetics and Gene Therapy work, reviewed by the scientific committee.
Network Globally
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Publish & Get Indexed
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Learn from Keynotes
Plenary lectures from leading voices shaping Ocular Genetics and Gene Therapy research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same program, same certificate.
Join IOC 2027 for the Ocular Genetics and Gene Therapy track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Ocular Genetics and Gene Therapy Conference 2027 — FAQs
What is the Ocular Genetics and Gene Therapy track at IOC 2027?
The Ocular Genetics and Gene Therapy track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Ocular Genetics and Gene Therapy. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Ocular Genetics and Gene Therapy sessions?
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Ocular Genetics and Gene Therapy are all welcome — whether presenting or attending.
Can I present my research in the Ocular Genetics and Gene Therapy track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Ocular Genetics and Gene Therapy sessions?
Yes. IOC 2027 is a hybrid conference — attend the Ocular Genetics and Gene Therapy track in person in Singapore or join live online, with on-demand access afterward.
Join the IOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Register as Delegate →
Attend without presenting.